Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Why is Iron Deficiency Recognised as an Important Comorbidity in Heart Failure?
Author(s): Rajalakshmi Santhanakrishnan Added: 3 years ago
Heart failure (HF) is a major health problem and about 6 million adults are affected in the US alone, at a cost of approximately $20 billion per year.1 Despite the availability of new treatment strategies, the incidence, number of hospitalizations and mortality associated with HF remains a big health burden.1 In addition to increasing age, the factors that contribute to poor prognosis for people… View more

Heart Failure
ESC 23: The HEART-FID Study
Author(s): Robert Mentz Added: 7 months ago
ESC 2023 — Dr Robert Mentz (Duke University Medical Center, US) joins us to provide a succinct summary of the findings and key take-home messages from the HEART-FID study (NCT03037931). HEART-FID(American Regent, Inc.) aimed to determine the safety and efficacy of iron therapy using intravenous (IV) ferric carboxymaltose (FCM) as compared to a placebo in the treatment of patients with heart… View more

Heart Failure
HFA 23: IRONMAN: Anemia, Iron Deficiency and Quality of Life
Author(s): Paul Kalra Added: 10 months ago
ESC-HFA 23 – Prof Paul Kalra (Portsmouth Hospitals NHS Trust, UK) joins us onsite to discuss the IRONMAN trial (NCT02642562). The IRONMAN trial aimed to study the effectiveness of intravenous iron in patients with heart failure and iron deficiency when compared to standard care. It showed that administration of IV FDI led to lower rates of recurrent heart failure hospitalisations and… View more

Heart Failure
Association Between AID/FID with Incident CV Disease and Mortality
Author(s): Benedikt Schrage Added: 2 years ago
In this short video, Dr Benedikt Schrage (University Heart and Vascular Center Hamburg, DE) summarises the main findings from the analysis that looked into the association between AID/FID with incident CV disease and mortality in 2 164 individuals from three European population-based cohorts. The study, published in the ESC Heart Failure (2021), found that attributable risks ofFID for the tested… View more

Standards & Guidelines

Heart Failure
The IRONMAN Trial
Author(s): Paul Kalra Added: 1 year ago
Iron deficiency is common in heart failure, particularly in hospitalised patients and may exacerbate symptoms and increase the risk of hospitalisation and premature mortality. Although previous studies have shown that intravenous iron provides improvement in exercise capacity and reduces hospitalisation in patients with HF and iron deficiency, longer term efficacy and safety data has been lacking… View more

Heart Failure

Prevention & Chronic Conditions
Radcliffe & CardioNerds @AHA22: IRONMAN: Intravenous Ferric Derisomaltose in HF With Reduced EF
Author(s): Rawan Amir , Paul Kalra Added: 1 year ago
AHA 22 - Dr Rawan Amir, CardioNerds Fellow (Johns Hopkins Hospital, US) joins us in this collaboration between the @CardioNerds and Radcliffe Cardiology to interview Dr Paul Kalra (Portsmouth Hosp Univ NHS Trust, UK), investigator of the late-breaking IRONMAN trial (NCT02642562). This randomised, open-label multicentre trial assessed the effectiveness of intravenous iron treatment compared to… View more

Standards & Guidelines

Heart Failure
HFA 23: IRONMAN: Reasons for Hospitalisation and Biomarkers
Author(s): John GF Cleland Added: 10 months ago
ESC-HFA 23 - Prof John Cleland (University of Glasgow, UK) joins us onsite to discuss the IRONMAN trial (NCT02642562). IRONMAN was a randomised, open-label multicenter trial, which aimed to assess the effectiveness of intravenous iron in patients with heart failure and iron deficiency as compared to standard care. It demonstrated that the administration of IV FDI was associated with lower rates… View more

Heart Failure